Alzheimer Disease: Logroscino G

Kurth T, Logroscino G. · No affiliation provided · Stroke. · Pubmed #16397177 links to  free full text

This publication has no abstract.

Hernán MA, Alonso A, Logroscino G. · Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA. · Epidemiology. · Pubmed #18414087 No free full text.

Abstract: We conducted a systematic review of published prospective studies that estimated the association between smoking and the incidence of Alzheimer disease and dementia. The relative rate for smokers versus nonsmokers ranged from 0.27 to 2.72 for Alzheimer disease (12 studies) and from 0.38 to 1.42 for dementia (6 studies). The minimum age at entry (range: 55-75 years) explained much of the between-study heterogeneity in relative rates. We conjecture that selection bias due to censoring by death may be the main explanation for the reversal of the relative rate with increasing age.

Bowirrat A, Oscar-Berman M, Logroscino G. · The Galilee Society and An-Najah University, Nablus PA, Shefa-Amr, Israel. · Int J Geriatr Psychiatry. · Pubmed #16477584 No free full text.

Abstract: OBJECTIVES: Because dementia and depression share common risk factors, we investigated risk factors for depression in Arab subjects with Alzheimer's disease (AD) and vascular dementia (VaD). METHODS: In a cross-sectional population-based study, we conducted a door-to-door survey of all adults over age 60 in an Arab community of rural Israel. We conducted interviews, gave questionnaires, and collected DNA blood specimens for determination of ApoE genotype. RESULTS: Of the 823 individuals in this naturalistic sample, 168 had dementia of Alzheimer's type (DAT) and 49 had VaD. Vascular risk factors, including the ApoE-epsilon4 allele, were more prevalent among VaD than DAT subjects. Depressive symptoms were present in 57% of DAT patients and 86% of VaD patients. Depressed DAT individuals had a greater history of ischemic cardiovascular or cerebrovascular (CV/CBV) disease than non-depressed DAT subjects, but depressed DAT subjects were less likely to have the ApoE-epsilon4 allele. Within the VaD group, there was no difference in the distribution of cardiovascular risk factors in individuals with and without depressive symptoms, and ApoE-epsilon4 was more prevalent among subjects with depressive symptoms. CONCLUSIONS: Depressive symptomatology is prevalent among subjects with dementias in this Arab community. History of CV/CBV is associated with the presence of depressive symptoms in DAT. Further studies are needed to clarify the role of ApoE in depression onset in different ethnic groups with DAT.

Kang JH, Logroscino G, De Vivo I, Hunter D, Grodstein F. · Department of Medicine, Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, 181 Longwood Ave., Boston, MA 02115, USA. · Neurobiol Aging. · Pubmed #15653176 No free full text.

Abstract: The apolipoprotein E (APOE) e4 allele increases risk of Alzheimer disease and cardiovascular diseases. We examined APOE genotypes alone or combined with cardiovascular conditions in relation to cognitive function in 4227 Nurses' Health Study participants, 70-80 years old. From 1995 to 2001, and again 2 years later, participants received telephone cognitive assessments of general cognition, category fluency, verbal memory and working memory. In biennial questionnaires since 1976, participants have provided extensive health information including cardiovascular conditions. Compared with women with the e3/3 genotype, e4 carriers performed worse at baseline across all tests (mean global composite score was lower by 0.10 points (95% confidence interval=-0.15, -0.05)) and declined more (mean change in global score was -0.07 points (95% CI=-0.12, -0.03)), with a strong allele dose-response trend (P-trend=0.0003). Among participants 75+ years, e2 carriers performed best. Women with an e4 allele and cardiovascular conditions such as transient ischemic attack or untreated hypertension had the worst cognition. Thus, APOE genotypes strongly influenced cognitive function and decline; prevention of cardiovascular disease may limit these effects.